Volume | 175,420 |
|
|||||
News | - | ||||||
Day High | 10.99 | Low High |
|||||
Day Low | 9.83 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Solid Biosciences Inc | SLDB | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
10.44 | 9.83 | 10.99 | 10.39 | 10.34 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
2,579 | 175,420 | $ 10.04 | $ 1,761,335 | - | 1.81 - 15.05 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
17:12:59 | 25 | $ 10.20 | USD |
Solid Biosciences Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
392.67M | 37.76M | - | 0 | -96.02M | -2.54 | - |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | - | - | - |
Solid Biosciences News
Loading Messages....
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical SLDB Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 10.33 | 10.99 | 9.78 | 10.16 | 239,425 | 0.06 | 0.58% |
1 Month | 10.75 | 10.99 | 7.95 | 9.57 | 202,753 | -0.36 | -3.35% |
3 Months | 9.96 | 15.05 | 7.95 | 11.47 | 249,523 | 0.43 | 4.32% |
6 Months | 2.19 | 15.05 | 2.00 | 6.65 | 476,225 | 8.20 | 374.43% |
1 Year | 5.94 | 15.05 | 1.81 | 6.51 | 248,975 | 4.45 | 74.92% |
3 Years | 70.95 | 74.25 | 1.81 | 24.91 | 547,060 | -60.56 | -85.36% |
5 Years | 145.05 | 203.70 | 1.81 | 55.02 | 860,623 | -134.66 | -92.84% |
Solid Biosciences Description
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of speciality and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. Its lead product candidate, the SGT-001, is a gene transfer under development to restore functional dystrophin protein expression in patients' muscles. The company's pipeline products are the SB-001 and solid suit. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices. |